ArticleP & T : a peer-reviewed journal for formulary management2008
Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched from Fixed-Dose To Free-Combination Antihypertensive Therapy.
Article in P & T : a peer-reviewed journal for formulary management, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Medication adherence with fixed-doseFrontiers in pharmacology · 2023Pooled it
- The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2018Pooled it
- Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence.Journal of clinical hypertension (Greenwich, Conn.) · 2011Pooled it
- Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.Drugs & aging · 2013Trial
- Fixed-dose combinationFrontiers in pharmacology · 2026Article
- Fixed-dose combination antihypertensive therapy and healthcare utilization in U.S. adults with hypertension: a propensity score-based analysis of a nationally representative population.Frontiers in pharmacology · 2026Article
- Starting Antihypertensive Drug Treatment With Combination Therapy: Controversies in Hypertension - Con Side of the Argument.Hypertension (Dallas, Tex. : 1979) · 2021Article
- Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review.Pharmaceutics · 2020Review
- Fixed-dose combination antihypertensives and risk of medication errors.Heart (British Cardiac Society) · 2019Observational
- Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis.Archives of medical science : AMS · 2018Review
- Fixed-dose vs free-dose combinations for the management of hypertension-An analysis of 81 958 patients.Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- Efficacy and tolerability of telmisartan plus amlodipine in asian patients not adequately controlled on either monotherapy or on low-dose combination therapy.International journal of hypertension · 2014Article
- A review of the efficacy and tolerability of combination amlodipine/valsartan in non-white patients with hypertension.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2013Review
- The TRINITY Study: distribution of systolic blood pressure reductions.Integrated blood pressure control · 2013Article
- Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension.Vascular health and risk management · 2013Review
- Valsartan combination therapy in the management of hypertension - patient perspectives and clinical utility.Integrated blood pressure control · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using a retrospective cohort study of medical and pharmacy claims data, we evaluated medication compliance, persistence, and hypertension-related expenditures among patients who were switched from fixed-dose combination (FDC) to free-combination (FC) antihypertensive therapy. An example of a fixed-dose combination product for hypertension would be a valsartan/HCT tablet, and a free-combination product would be a valsartan tablet plus a diuretic tablet.The 7,224 patients identified from January 2003 to December 2005 were matched, in a 1:1 ratio, by propensity scores to controls who remained on their FC antihypertensive medications. Compliance, defined as a medication-possession ratio, was measured over 12 months. Persistence was measured as the percentage of patients who did not experience a lapse in therapy of more than 30 days since their last prescription refill.The patients continuing with FDC therapy had better persistence (42.5% higher; P < 0.002) and compliance (22.1% higher; P < 0.001), compared with patients who were switched to FC therapy. The 22.1% higher compliance rate for patients continuing the FDC regimen was associated with significantly lower expenditures for hypertension-related health care (P < 0.001) and an estimated 5% reduction in hypertension-related expenditures.
Indexed as
Identifiers
19750061PMC2730815W1654074420What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.